Effects of CROCUVIS+® on Computer Vision Syndrome, Sleep and Mood Disorders

Sleep Disorder Clinical Trial

Official title:

Effects of CROCUVIS+® on Computer Vision Syndrome, Sleep and Mood Disorders

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05211063
• Other study ID #: PHARMACTIVE-21TPA
• Status: Completed
• Phase: N/A
• Start date: October 21, 2022
• Est. completion date: May 5, 2023

Study information

• Verified date: May 2023
• Source: University of Alicante
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Previous research has shown the efficacy of CROCUVIS+® dietary supplement, based on saffron extract, in the proper functioning of visual health, for example, against the development of glaucoma. The main objective of this study is to evaluate the efficacy of CROCUVIS® in computer vision syndrome, sleep and mood disorders in a sample of university students who use digital devices.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: May 5, 2023
• Est. primary completion date: December 27, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• CVS-Q© score =6.
• Age between 18 and 40 years (both inclusive).
• Exposure to digital devices 4 hours a day, at least five days a week or more and maintain the same level of exposure throughout the study period.

Exclusion Criteria:

• Monocular corrected distance visual acuity >0.0 LogMAR.
• Ocular pathology under treatment at the time of the study.
• Previous ocular surgery that could affect the tear film or the ocular surface.
• Ocular Surface Disease Index (OSDI) questionnaire score =13.
• Previous diagnosis or history of dry eye syndrome and/or blepharitis.
• Regular (daily) use of rigid or soft contact lenses =3 days a week.
• Regular use of any ocular lubricant.
• History of oral intake of dietary supplements, with or without herbal ingredients, intended to contribute, maintain or reduce the risk of suffering diseases related to visual function, mood or sleep within the four weeks before the study enrollment.
• Systemic disease:

1. Uncontrolled hypertension (systolic/diastolic blood pressure >140/90 mmHg).

2. Uncontrolled diabetes mellitus (fasting blood glucose level >180 mg/dL).

3. Rheumatoid arthritis.

4. Tumor disease.

5. Active hepatitis (type B and C).

6. Active infectious disease.

7. Kidney disease that compromises diuresis.

• Current systemic treatment or in the last 3 months with drugs that may interfere with

the results, for example:

1. Opioids.

2. Antipsychotics.

3. Antibiotics (tetracyclines, sulfonamides)

4. Antiarthritic drugs (hydroxychloroquine)

5. Hypotensive drugs (beta-blockers)

6. Anticoagulants (heparin, warfarin, or clopidogrel)

7. Antidepressants (such as fluoxetine, among others)

8. Hypnotics (eg, benzodiazepines)

• Habitual smoker and/or alcohol drinker. More than 3 cigarettes per day and/or more than 3 Standard Drink Units (SDU) per week, including weekends. SDU is defined as the consumption of 10 ml of alcohol.
• Regular job with rotating shifts including night shift in the last month (including weekends).
• Pregnancy or breastfeeding (also excludes recent pregnancy within the last 3 months) and women planning to become pregnant.
• Participation in another clinical trial in the last 3 months.
• Take any type of dietary supplements with botanical components in the last month.

Related Conditions & MeSH terms

• Computer Vision Syndrome
• Disease
• Mood Disorders
• Sleep Disorder
• Sleep Wake Disorders
• Syndrome

Intervention

Dietary Supplement:
• Saffron extract (Crocus sativus)
Daily intake of one tablet for 42 days.
• Placebo
Daily intake of one tablet for 42 days.

Locations

Country	Name	City	State
Spain	University of Alicante	San Vicente Del Raspeig	Alicante

Sponsors (2)

Lead Sponsor	Collaborator
University of Alicante	Pharmactive Biotech Products S.L.U

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline computer vision syndrome at 14, 28 and 42 days	Measured with the Computer Vision Syndrome Questionnaire (CVS-Q©). It evaluates the frequency and intensity with which 16 symptoms are perceived over the time of use of digital devices. The score ranges from 0 to 32; computer vision syndrome is considered =6. The higher score a subject gained, the worsen ocular condition he/she experienced.	0 (baseline), 14, 28 and 42 days
Primary	Change from baseline sleep disorders at 14, 28 and 42 days	Measured with the Insomnia Severity Index (ISI). It evaluates 7 items. The score ranges from 0 to 28 (worst). Each item is evaluated on a 5-point Likert scale (from 0 to 4). The final score is obtained from the sum of the responses of all items; insomnia is considered =8.	0 (baseline), 14, 28 and 42 days
Primary	Change from baseline mood at 14, 28 and 42 days	Measured with the Profile of Mood States (POMS). It evaluates 58 items that form 6 factors (tension, depression, anger, vigour, fatigue, and confusion). The score ranges from 68 to 300 (worst mood). Each item is evaluated with a 5-point Likert scale (from 0 to 4). The score of each factor is obtained from the sum of the responses of all the items that define it.; Total Mood Disturbance = 100+ (Tension + Depression + Anger + Fatigue + Confusion) - Vigour	0 (baseline), 14, 28 and 42 days
Secondary	Change from baseline quality of life related to health at 42 days	Measured with Short Form-36 survey (SF-36). It evaluates 36 items that form 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, mental health). The scores are weighted sums of the questions in each section. The score ranges from 0 to 100. Lower scores = more disability, higher scores = less disability.	0 (baseline) and 42 days
Secondary	Satisfaction question	A single satisfaction question. Participants must respond by selecting a number from a Likert scale from 0 to 5.	Last visit (42 day)